Transgene

Stocks

Real-time Euronext Paris 09:02:37 2026-10-21 am EDT			5-day change	1st Jan Change
0.6750 ^EUR	-1.03%		-2.17%	-29.69%

Sep. 25	Transgene provides update on its operations
Sep. 08	Transgene Expands ProBioGen Partnership With Additional License	MT

Published on 06/29/2026 at 10:35 am EDT - Modified on 06/29/2026 at 04:52 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Transgene virtual key opinion leader event. At this time, all attendees are in a listen-only mode and a

[

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Sep. 25	Transgene provides update on its operations
Sep. 08	Transgene Expands ProBioGen Partnership With Additional License	MT
Sep. 03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
Sep. 02	Transgene: no cases of recurrence at three years among patients treated with TG4050
Sep. 02	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
Jun. 29	Transgene SA - Special Call
Jun. 25	Oddo BHF Stays Positive on Transgene
Jun. 25	Positive Preclinical Data for a Transgene Vaccine
Jun. 25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
Jun. 22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
Jun. 22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
Jun. 22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
May. 22	Transgene SA Announces Board Appointments	CI
Apr. 13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
Apr. 07	Transgene stands out following licensing agreement with NEC Bio

Duration

Period

Sector